Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for MNICF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
May 31, 2026 21.04%
February 28, 2026 24.18%
November 30, 2025 24.22%
August 31, 2025 5.06%
May 31, 2025 17.59%
February 28, 2025 18.76%
November 30, 2024 20.88%
August 31, 2024 17.44%
May 31, 2024 24.55%
February 29, 2024 23.82%
November 30, 2023 22.11%
August 31, 2023 29.29%
May 31, 2023 25.28%
February 28, 2023 21.35%
November 30, 2022 21.28%
August 31, 2022 26.85%
May 31, 2022 28.13%
February 28, 2022 20.54%
November 30, 2021 27.96%
August 31, 2021 19.06%
May 31, 2021 31.66%
February 28, 2021 25.09%
November 30, 2020 23.43%
August 31, 2020 14.38%
May 31, 2020 16.05%
Date Value
February 29, 2020 30.41%
November 30, 2019 24.17%
August 31, 2019 21.90%
May 31, 2019 22.84%
February 28, 2019 22.10%
November 30, 2018 64.29%
August 31, 2018 20.46%
May 31, 2018 19.63%
February 28, 2018 16.86%
November 30, 2017 17.91%
August 31, 2017 17.97%
May 31, 2017 18.19%
February 28, 2017 20.46%
November 30, 2016 20.87%
August 31, 2016 15.97%
May 31, 2016 24.70%
February 29, 2016 17.57%
November 30, 2015 14.08%
August 31, 2015 17.10%
May 31, 2015 25.49%
February 28, 2015 19.75%
November 30, 2014 24.04%
August 31, 2014 21.40%
May 31, 2014 22.87%
February 28, 2014 25.15%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Terumo Corp. 22.59%
Nipro Corp. 2.81%
HOYA Corp. 25.74%
Nakanishi, Inc. 16.83%
Abbott Laboratories 7.37%